ArticlePLoS computational biology2014
Antibody responses during hepatitis B viral infection.
Article in PLoS computational biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 90 citations in OpenAlex.
- Clinical trial simulation of antiviral drugs.Journal of virology · 2026Review
- A Quantitative Systems Pharmacology (QSP) Model of Acute Hepatitis B Virus Infection: Mechanistic Insights and Foundations for Future Extensions.CPT: pharmacometrics & systems pharmacology · 2026Article
- Bistability between acute and chronic states in a Model of Hepatitis B Virus Dynamics.Mathematical biosciences · 2025Article
- A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B.PLoS computational biology · 2025Article
- Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection.CPT: pharmacometrics & systems pharmacology · 2025Review
- Understanding antibody magnitude and durability following vaccination against SARS-CoV-2.Mathematical biosciences · 2024Article
- How robust are estimates of key parameters in standard viral dynamic models?PLoS computational biology · 2024Article
- Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers.PLoS computational biology · 2024Article
- Antigen Recognition and Immune Response to Acute and Chronic Hepatitis B Virus Infection.Journal of inflammation research · 2023Review
- Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis.Frontiers in immunology · 2022Article
- Comparing antiviral strategies against COVID-19 via multiscale within-host modelling.Royal Society open science · 2021Article
- Early events in hepatitis B infection: the role of inoculum dose.Proceedings. Biological sciences · 2021Article
- Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection.Scientific reports · 2021Article
- A quantitative systems pharmacology model for acute viral hepatitis B.Computational and structural biotechnology journal · 2021Article
- Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01.Frontiers in immunology · 2021Article
- The impact of testing and treatment on the dynamics of Hepatitis B virus.F1000Research · 2021Article
- An Intracellular Model of Hepatitis B Viral Infection: An In Silico Platform for Comparing Therapeutic Strategies.Viruses · 2020Article
- Protein Kinase C subtype δ interacts with Venezuelan equine encephalitis virus capsid protein and regulates viral RNA binding through modulation of capsid phosphorylation.PLoS pathogens · 2020Article
- The immunoglobulin γ marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humans.Immunology · 2020Article
- Within-host mathematical models of hepatitis B virus infection: Past, present, and future.Current opinion in systems biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatitis B is a DNA virus that infects liver cells and can cause both acute and chronic disease. It is believed that both viral and host factors are responsible for determining whether the infection is cleared or becomes chronic. Here we investigate the mechanism of protection by developing a mathematical model of the antibody response following hepatitis B virus (HBV) infection. We fitted the model to data from seven infected adults identified during acute infection and determined the ability of the virus to escape neutralization through overproduction of non-infectious subviral particles, which have HBs proteins on their surface, but do not contain nucleocapsid protein and viral nucleic acids. We showed that viral clearance can be achieved for high anti-HBV antibody levels, as in vaccinated individuals, when: (1) the rate of synthesis of hepatitis B subviral particles is slow; (2) the rate of synthesis of hepatitis B subviral particles is high but either anti-HBV antibody production is fast, the antibody affinity is high, or the levels of pre-existent HBV-specific antibody at the time of infection are high, as could be attained by vaccination. We further showed that viral clearance can be achieved for low equilibrium anti-HBV antibody levels, as in unvaccinated individuals, when a strong cellular immune response controls early infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.